Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study.

BACKGROUND

Anti-TNFα represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs.

AIMS

To assess the treatment patterns with the first anti-TNFα in IBD.

METHODS

Retrospective, observational study.

RESULTS

310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC.

CONCLUSIONS

Around one-third of IBD biologic-naive patients treated with an anti-TNFα required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNFα due to inappropriate disease control.

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflict of Interest Guillermo Bastida has received a speaker honorarium from Abvvie, Pfizer, Janssen, FAES, Takeda, Tillots and Abbott. Also, Guillermo Bastida has participated in Scientific Advisory Comitees of Takeda, Janssen and Abvvie. Ignacio Marín-Jiménez has served as a consultant, advisory member, speaker, or has received research funding from MSD, Abbvie, Takeda, Tillots, Ferring, Falk-Pharma, Faes Farma, UCB Pharma, Otsuka Pharmaceutical, Shire, Gebro Pharma, and Chiesi. Ana Forés has nothing to declare. Esther García-Planella has served as a speaker or received research or educational funding or advisory fees from MSD, Abbvie, Jansen, Ferring, Shire, Tillots, Faes. Federico Argüelles-Arias has served as a speaker, a consultant and as an advisory member for or have received research funding from Janssen, MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Sandoz, Takeda, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Gebro Pharma, Amgen and Vifor Pharma. Ignacio Tagarro, Alonso Fernandez-Nistal, Carmen Montoto and Jesús Aparicio are full employees of Takeda Farmacéutica España. Mariam Aguas has served as a speaker for MSD, Abbvie, Janssen, Takeda and Tillots, and received educational grants from Janssen, MSD and Abbvie. Javier Santos-Fernández has nothing to declare. Marta Maia Bosca-Watts declares educational activities, research projects, scientific meetings and advisory boards sponsored by MSD, Ferring, Abbvie, Janssen and Takeda. Rocío Ferreiro-Iglesias has served as a speaker for or has received research funding from Takeda, MSD, Abbvie, Janssen, Palex, Shire Pharmaceuticals, TillottsPharma and Casenrecordati. Olga Merino has nothing to declare. Xavier Aldeguer has nothing to declare. Xavier Cortes has nothing to declare. Beatriz Sicilia has nothing to declare. Francisco Mesonero has served as a speaker or consultant from MSD, Takeda, Janssen, Abbvie and Ferring. Manuel Barreiro-de Acosta has served as a speaker, a consultant and advisory board member for, or has received research funding from, MSD, Abbvie, Janssen, Pfizer, Kern Pharma, Biogen, Takeda, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Gebro Pharma, Otsuka Pharmaceutical and Vifor Pharma.